Primary endpoint
toxicities, Skin toxicities
SKIN
Skin toxicities (Grade ≥2) occurred in 43.9% (90% CI, 31.2%–56.7%) of the enrolled patients during the initial 8 weeks of dacomitinib therapy, which did not meet the primary endpoint (Skin toxicities in the initial 8 weeks of treatment (